Meeting Archive:
Optimizing GIST Treatment


Meeting Description:
Are you interested in optimizing your treatment?
 
A world-renown GIST expert from Europe will share his wealth of experience and insight about how he has helped patients live longer and how he consults with fellow physicians on the best treatment plan for their patients.
 
Dr. Peter Reichardt is Assistant Professor and Head of the Department of Oncology and Palliative Care at the Helios Klinikum Berlin-Buch in Berlin, Germany, and is Director of the Cancer Center Berlin-Buch and the Sarcoma Center Berlin-Brandenburg.
 
In this webcast, Dr. Reichardt will discuss surgery for metastatic disease, imatinib plasma level testing, and the management of side effects.
 
He will also cover: dosing, dose escalation and dose schedules, and will explain mutations and the importance of mutational testing.
 
There will be a 15 minute Q & A at the end of the presentation.
Details
Date: Thu, May 16, 2019
Time: 12:00 PM EDT
Duration: 1 hour
Host(s): Sara Rothschild
 Presenter Information
Dr. Peter Reichardt
Speaker Photo

Peter Reichardt is Assistant Professor and Head of the Department of Oncology and Palliative Care at the Helios Klinikum Berlin-Buch in Berlin, Germany, and is Director of the Cancer Center Berlin-Buch and the Sarcoma Center Berlin-Brandenburg. Dr Reichardt has led and conducted multiple clinical trials in bone sarcomas, soft tissue sarcomas and gastrointestinal stromal tumours in the adjuvant, advanced, and refractory settings. Dr Reichardt is a co-author of the current European Society for Medical Oncology (ESMO) guidelines for the management of GIST, soft tissue and bone sarcomas and a member of the ESMO Sarcoma Faculty. He is Chairman of the Scientific Committee of the GIST and Sarcoma patients’ organization ‘Das Lebenshaus’, a member of the Medical Board of the MAX Foundation, and a member of the Life Raft Group´s Global GIST Advisory Team. Dr Reichardt has contributed to numerous publications on soft tissue sarcoma and GIST management in leading oncology journals.